Cargando…
Performance evaluation of in vitro diagnostic kits for hepatitis B virus infection using the regional reference panel of Japan
BACKGROUND: Hepatitis B virus (HBV) infection is a global public health concern. Precise and sensitive detection of viral markers, including HBV DNA and HBs antigen (Ag), is essential to determine HBV infection. METHODS: The sensitivities and specificities of 5 HBV DNA and 14 HBsAg kits were evaluat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170722/ https://www.ncbi.nlm.nih.gov/pubmed/37165426 http://dx.doi.org/10.1186/s12985-023-02054-7 |
_version_ | 1785039281537941504 |
---|---|
author | Momose, Haruka Murayama, Asako Yamada, Norie Matsubayashi, Keiji Matsuoka, Sahoko Ikebe, Emi Kuramitsu, Madoka Muramatsu, Masamichi Kato, Takanobu Hamaguchi, Isao |
author_facet | Momose, Haruka Murayama, Asako Yamada, Norie Matsubayashi, Keiji Matsuoka, Sahoko Ikebe, Emi Kuramitsu, Madoka Muramatsu, Masamichi Kato, Takanobu Hamaguchi, Isao |
author_sort | Momose, Haruka |
collection | PubMed |
description | BACKGROUND: Hepatitis B virus (HBV) infection is a global public health concern. Precise and sensitive detection of viral markers, including HBV DNA and HBs antigen (Ag), is essential to determine HBV infection. METHODS: The sensitivities and specificities of 5 HBV DNA and 14 HBsAg kits were evaluated using World Health Organization International Standards (WHO IS) and the Regional Reference Panel (RRP) consisting of 64 HBsAg-negative and 80 HBsAg-positive specimens. RESULTS: All 5 HBV DNA kits detected HBV DNA in the WHO IS at a concentration of 10 IU/mL. The sensitivity and specificity to the RRP were 98.8–100% and 96.9–100%, respectively. HBV DNA titers were well correlated among the 5 kits regardless of HBV genotype. However, discordance of the HBV DNA titer was found in 5 specimens measured by CAP/CTM HBV v2.0. Among 12 automated HBsAg kits, the minimum detectable concentrations in the WHO IS varied from 0.01 to 0.1 IU/mL. Two lateral flow assays were positive for WHO IS concentrations greater than or equal to 1.0 and 0.1 IU/mL, respectively. When analyzed by the RRP, 12 automated kits exhibited a sensitivity of 98.8–100%, and 2 lateral flow assays showed sensitivities of 93.8% and 100%. The specificities of HBsAg kits were 100%. In the quantification of HBsAg, some kits showed a poor correlation of measurements with each other and showed up to a 1.7-fold difference in the regression coefficient of HBsAg titers. There were variations in the correlations of measurements among HBsAg kits when analyzed by genotype. CONCLUSIONS: Five HBV DNA kits showed sufficient sensitivity and specificity to determine HBV infection. HBV DNA titers were compatible with each other irrespective of HBV genotypes. HBsAg kits had enough sensitivity and specificity to screen for HBV infection. One of the lateral flow assays had a nearly equivalent sensitivity to that of the automated HBsAg kit. HBsAg titers quantified by the evaluated kits were not compatible across the kits. Genotype-dependent amino acid variations might affect the quantification of HBsAg titers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02054-7. |
format | Online Article Text |
id | pubmed-10170722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101707222023-05-11 Performance evaluation of in vitro diagnostic kits for hepatitis B virus infection using the regional reference panel of Japan Momose, Haruka Murayama, Asako Yamada, Norie Matsubayashi, Keiji Matsuoka, Sahoko Ikebe, Emi Kuramitsu, Madoka Muramatsu, Masamichi Kato, Takanobu Hamaguchi, Isao Virol J Research BACKGROUND: Hepatitis B virus (HBV) infection is a global public health concern. Precise and sensitive detection of viral markers, including HBV DNA and HBs antigen (Ag), is essential to determine HBV infection. METHODS: The sensitivities and specificities of 5 HBV DNA and 14 HBsAg kits were evaluated using World Health Organization International Standards (WHO IS) and the Regional Reference Panel (RRP) consisting of 64 HBsAg-negative and 80 HBsAg-positive specimens. RESULTS: All 5 HBV DNA kits detected HBV DNA in the WHO IS at a concentration of 10 IU/mL. The sensitivity and specificity to the RRP were 98.8–100% and 96.9–100%, respectively. HBV DNA titers were well correlated among the 5 kits regardless of HBV genotype. However, discordance of the HBV DNA titer was found in 5 specimens measured by CAP/CTM HBV v2.0. Among 12 automated HBsAg kits, the minimum detectable concentrations in the WHO IS varied from 0.01 to 0.1 IU/mL. Two lateral flow assays were positive for WHO IS concentrations greater than or equal to 1.0 and 0.1 IU/mL, respectively. When analyzed by the RRP, 12 automated kits exhibited a sensitivity of 98.8–100%, and 2 lateral flow assays showed sensitivities of 93.8% and 100%. The specificities of HBsAg kits were 100%. In the quantification of HBsAg, some kits showed a poor correlation of measurements with each other and showed up to a 1.7-fold difference in the regression coefficient of HBsAg titers. There were variations in the correlations of measurements among HBsAg kits when analyzed by genotype. CONCLUSIONS: Five HBV DNA kits showed sufficient sensitivity and specificity to determine HBV infection. HBV DNA titers were compatible with each other irrespective of HBV genotypes. HBsAg kits had enough sensitivity and specificity to screen for HBV infection. One of the lateral flow assays had a nearly equivalent sensitivity to that of the automated HBsAg kit. HBsAg titers quantified by the evaluated kits were not compatible across the kits. Genotype-dependent amino acid variations might affect the quantification of HBsAg titers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02054-7. BioMed Central 2023-05-10 /pmc/articles/PMC10170722/ /pubmed/37165426 http://dx.doi.org/10.1186/s12985-023-02054-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Momose, Haruka Murayama, Asako Yamada, Norie Matsubayashi, Keiji Matsuoka, Sahoko Ikebe, Emi Kuramitsu, Madoka Muramatsu, Masamichi Kato, Takanobu Hamaguchi, Isao Performance evaluation of in vitro diagnostic kits for hepatitis B virus infection using the regional reference panel of Japan |
title | Performance evaluation of in vitro diagnostic kits for hepatitis B virus infection using the regional reference panel of Japan |
title_full | Performance evaluation of in vitro diagnostic kits for hepatitis B virus infection using the regional reference panel of Japan |
title_fullStr | Performance evaluation of in vitro diagnostic kits for hepatitis B virus infection using the regional reference panel of Japan |
title_full_unstemmed | Performance evaluation of in vitro diagnostic kits for hepatitis B virus infection using the regional reference panel of Japan |
title_short | Performance evaluation of in vitro diagnostic kits for hepatitis B virus infection using the regional reference panel of Japan |
title_sort | performance evaluation of in vitro diagnostic kits for hepatitis b virus infection using the regional reference panel of japan |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170722/ https://www.ncbi.nlm.nih.gov/pubmed/37165426 http://dx.doi.org/10.1186/s12985-023-02054-7 |
work_keys_str_mv | AT momoseharuka performanceevaluationofinvitrodiagnostickitsforhepatitisbvirusinfectionusingtheregionalreferencepanelofjapan AT murayamaasako performanceevaluationofinvitrodiagnostickitsforhepatitisbvirusinfectionusingtheregionalreferencepanelofjapan AT yamadanorie performanceevaluationofinvitrodiagnostickitsforhepatitisbvirusinfectionusingtheregionalreferencepanelofjapan AT matsubayashikeiji performanceevaluationofinvitrodiagnostickitsforhepatitisbvirusinfectionusingtheregionalreferencepanelofjapan AT matsuokasahoko performanceevaluationofinvitrodiagnostickitsforhepatitisbvirusinfectionusingtheregionalreferencepanelofjapan AT ikebeemi performanceevaluationofinvitrodiagnostickitsforhepatitisbvirusinfectionusingtheregionalreferencepanelofjapan AT kuramitsumadoka performanceevaluationofinvitrodiagnostickitsforhepatitisbvirusinfectionusingtheregionalreferencepanelofjapan AT muramatsumasamichi performanceevaluationofinvitrodiagnostickitsforhepatitisbvirusinfectionusingtheregionalreferencepanelofjapan AT katotakanobu performanceevaluationofinvitrodiagnostickitsforhepatitisbvirusinfectionusingtheregionalreferencepanelofjapan AT hamaguchiisao performanceevaluationofinvitrodiagnostickitsforhepatitisbvirusinfectionusingtheregionalreferencepanelofjapan |